Marijuana has the strongest evidence for treating chronic pain, chemotherapy-related nausea, certain severe epilepsy syndromes, and muscle spasticity from multiple sclerosis. Beyond those core uses, the picture gets murkier. Some conditions show promising early results, while others that were once considered good candidates for cannabis, like glaucoma, have largely been set aside in favor of better options. Here’s what the evidence actually supports.
How Cannabis Works in the Body
Your body has its own signaling network called the endocannabinoid system, with two main types of receptors. The first type sits primarily on nerve endings throughout the brain and nervous system, where it helps regulate the release of chemical messengers involved in pain, mood, appetite, and memory. The second type is concentrated in immune cells and plays a role in inflammation.
THC, the compound that produces the high, activates those nerve-based receptors directly. That’s why it can reduce pain signals, stimulate appetite, and calm nausea, but also cause sedation, anxiety, or impaired memory. CBD, the other major compound, doesn’t produce a high. It works through different pathways and has anti-inflammatory and anti-seizure properties. Most medical applications rely on one or both of these compounds, sometimes in specific ratios.
Chronic Pain
Pain is the most common reason people seek medical marijuana. Among patients applying for cannabis certifications, low back pain is the top complaint at 56%, followed by neck and extremity pain. The evidence is real but moderate. A large analysis of 47 randomized trials and 57 observational studies covering nearly 10,000 patients found that cannabinoids produced modest pain relief. About 29% of patients achieved a meaningful 30% reduction in pain, compared to 26% on placebo.
Neuropathic pain, the burning or shooting kind caused by nerve damage, has the most consistent support. Other pain types show less clear benefits. One 12-week study of THC, CBD, and a 1:1 combination found over 55% pain reduction with THC-containing formulations, with fibromyalgia patients responding particularly well. Broader estimates suggest CBD can reduce chronic pain by 42% to 66% in some populations, though results vary widely depending on the condition and the product used.
The appeal for many patients is that cannabis carries lower dependency risks than opioids. That trade-off matters in conditions requiring long-term pain management, where opioid side effects and addiction potential are serious concerns.
Chemotherapy-Induced Nausea
Cannabis-based treatments for nausea during chemotherapy have some of the longest-standing evidence. The FDA has approved two synthetic THC medications specifically for nausea in cancer patients who don’t respond well to standard anti-nausea drugs. A third approved medication uses a synthetic compound with a structure similar to THC for the same purpose.
A recent randomized, placebo-controlled trial tested capsules containing 2.5 mg THC plus 2.5 mg CBD, taken three times daily alongside standard anti-nausea medications. Among patients whose nausea and vomiting persisted despite conventional treatment, the cannabis extract tripled the complete response rate: 24% had full relief versus 8% on placebo. The need for rescue medications dropped similarly, from 91% on placebo to 72% with cannabis. The improvement exceeded the 10% threshold that guidelines committees consider significant enough to change treatment recommendations.
The most common bothersome side effects were sedation (18% vs. 7% on placebo) and dizziness (10% vs. 0%). Some patients experienced transient anxiety.
Epilepsy and Seizure Disorders
This is where cannabis has its most clear-cut success story. The FDA approved a purified CBD medication for treating seizures in patients two years and older with Lennox-Gastaut syndrome or Dravet syndrome, two severe forms of childhood epilepsy that often resist other treatments.
The results are striking. In real-world use, patients experienced a median reduction in motor seizures of about 57% at six months and 60% at twelve months. For families dealing with dozens or even hundreds of seizures per month, that level of improvement can be transformative. This is purified CBD, not whole-plant marijuana, and it works through mechanisms distinct from THC’s psychoactive effects.
Multiple Sclerosis Spasticity
Muscle stiffness and painful spasms are among the most disabling symptoms of MS, and cannabis has substantial evidence here. Pooled data from five randomized trials involving about 1,100 patients found that oral cannabinoids significantly increased the odds of achieving a clinically meaningful 30% reduction in spasticity symptoms compared to placebo. A mouth spray containing equal parts THC and CBD, already approved in several countries for this use, showed consistent modest improvements across seven trials of roughly 1,200 patients.
The key distinction is that the benefits show up most clearly in patient-reported symptoms like tightness, pain, and sleep disruption, rather than in clinical measurements of muscle tone. For patients living with daily spasticity, that subjective relief is what matters most.
Appetite and Weight Loss in HIV/AIDS
The FDA approved a synthetic THC medication for treating the severe appetite loss and wasting that can accompany AIDS. THC stimulates hunger through the same nerve receptors that give recreational users “the munchies,” and for patients losing dangerous amounts of weight, that effect can be medically valuable. This was one of the earliest recognized medical uses of cannabinoids, and it remains an approved indication today.
Where the Evidence Falls Short: Glaucoma
Marijuana’s reputation as a glaucoma treatment dates back to research from the 1970s and 1980s showing it could lower eye pressure. That much is true, but the effect only lasts three or four hours per dose. To maintain any meaningful pressure reduction, you’d need to take 18 to 20 mg of THC six to eight times a day, every day. The side effects at that dose would be debilitating, and modern glaucoma medications work far better with a single daily drop. The American Academy of Ophthalmology does not recommend marijuana for glaucoma.
How Different Forms Compare
The way you consume cannabis changes how quickly it works and how long it lasts. Smoking or vaping produces effects within seconds to a few minutes, peaking at 15 to 30 minutes and fading within two to three hours. Edibles take 30 to 90 minutes to kick in, peak at two to three hours, and can last 4 to 12 hours depending on the dose. That delayed onset is why edibles carry a higher risk of accidental overconsumption: people take more before the first dose has fully hit.
For medical use, this matters practically. Someone managing breakthrough nausea during chemotherapy might need the fast relief of inhaled cannabis, while someone treating chronic pain overnight might prefer the sustained duration of an edible. Sublingual oils and tinctures placed under the tongue exist as a middle ground, though research on their specific onset times remains limited.
Side Effects and Interactions
Common side effects include dry mouth, red eyes, fatigue, headaches, and coughing (with smoked forms). Some people experience nausea, anxiety, or memory problems, which is ironic for a plant often used to treat nausea and anxiety. At higher doses or in sensitive individuals, hallucinations and psychosis can occur.
Cannabis amplifies the effects of alcohol, affecting mood and reaction time more than either substance alone. It can also interact with blood-thinning medications and supplements. If you use cannabis before surgery, it may increase your need for anesthesia and raise the risk of complications like a rapid heart rate. These interactions are worth discussing with your care team before any planned procedure.
Legal Status in 2026
As of April 2026, the U.S. Department of Justice moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act. This is a significant shift from the previous Schedule I classification, which had categorized marijuana alongside heroin as having no accepted medical use. An expedited hearing process beginning in June 2026 is evaluating whether to reschedule marijuana more broadly. For now, state medical marijuana programs operate under this new federal framework, though rules still vary significantly from state to state.